Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 674200

First European JAK2-V617f interlaboratory quality control study carried out by the MPN&MPNR-Euronet (COST ACTION BM0902)


Pallisgaard, Niels; Hasselbach, Hans Carl; Cassinat, A.; Kjaer, Lars; Vorland, M.; Dicker, F.; Bellosillo, Beatriz; Kristensen, T.; Andersen, M.; Lippert, Eric et al.
First European JAK2-V617f interlaboratory quality control study carried out by the MPN&MPNR-Euronet (COST ACTION BM0902) // Abstracts of The 18th Congress of the European Hematology Association ; u: Haematologica 98 (2013) (S1)
Stockholm, Švedska, 2013. str. 115-115 (ostalo, međunarodna recenzija, sažetak, znanstveni)


CROSBI ID: 674200 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
First European JAK2-V617f interlaboratory quality control study carried out by the MPN&MPNR-Euronet (COST ACTION BM0902)

Autori
Pallisgaard, Niels ; Hasselbach, Hans Carl ; Cassinat, A. ; Kjaer, Lars ; Vorland, M. ; Dicker, F. ; Bellosillo, Beatriz ; Kristensen, T. ; Andersen, M. ; Lippert, Eric ; Schwarz, Jiri ; Bryon, J. ; Naguib, D. ; Nomdedeu, J. ; Aggerholm, A. ; Wojtaszewska, Marzena ; Andrikovics, H ; Marušić, Maruška ; Ayala, R ; Leibundgut, E ; Samuelson, E ; Lode, L ; Girodon, F ; Percy, Melanie ; Hermouet, Sylvie

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of The 18th Congress of the European Hematology Association ; u: Haematologica 98 (2013) (S1) / - , 2013, 115-115

Skup
Congress of the European Hematology Association (18 ; 2013)

Mjesto i datum
Stockholm, Švedska, 13.06.2013. - 16.06.2013

Vrsta sudjelovanja
Ostalo

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
1849G>T mutation in JAK2; MPN; quantification of JAK2-V617F; COST ACTION BM0902

Sažetak
Background: Analysis for the 1849G>T mutation in JAK2 (encoding JAK2- V617F) is routine in the diagnosis of myeloproliferative neoplasms (MPNs). The quantification of the allelic burden in JAK2- V617F positive patients is increasingly used to monitor treatment response of new targeted therapies as well as in transplanted patients. Aims:Across Europe the quantitative JAK2-V617F analysis is performed using a number of different assays and analysis platforms and calibration is therefore needed in order to standardise the results. Methods: Blood samples from 10 JAK2-V617F positive patients were aliquoted (1 ml) and sent out with overnight courier together with 4 reference DNA samples, a JAK2- V617F real time quantitative PCR (qPCR) reference assay and 4 DNA samples (blood samples were collected after informed consent according to the guidelines of the Danish Regional Science Ethics Committee). The reference DNAs were made from a 80 mL pool of normal donor DNA from blood samples by spiking four 10 fold dilutions of a 650 bp PCR product containing the JAK2-V617F mutation into 20 mL aliquots. The copy number of JAK2- V617F and JAK2 wild type in the 4 DNA pools were determined by qPCR and by digital PCR and the allelic ratios of JAK2- V617F were calculated to 75%, 23%, 2.9% and 0.2%, respectively. The qPCR reference assay (Larsen et al BJH 2007) that is recommended by the ELN for quantitative PCR (Jovanovic et al submitted) was prepared as 10 fold concentrated wild type and V617F mutant primer/probe mixtures. The 4 DNA samples contained either wild type DNA (normal donor DNA), V617F positive DNA (HEL cell line DNA), water (negative control) or normal donor DNA spiked with 1% JAK2- V617F. Two local JAK2-V617F positive DNA samples were also included and these were analysed as both non-diluted and ten fold diluted in order to identify a potential inhibition. Results: Twenty four laboratories from 13 European countries participated in the study. DNA from the 10 patient blood samples was purified according to local protocols. All samples were run in triplicates (or in duplicates in a few labs) with both the local JAK2-V617F assay and the supplied reference assay (384 qPCR wells per lab). Protocol information, Ct (PCR cycle) values and calculated copy numbers from the local assay were sent to Vejle for analysis (approximately 14, 000 data points). Although the reported copy numbers in the 10 patient samples varied between labs the percentage of JAK2-V617F alleles was rather consistent for both the local assay and the reference assay. All labs were able to indentify the 1% JAK2 V617F sample as positive when using the reference assay. However, in several labs the allelic burden of the 1% sample was not significantly different from the normal wild type DNA sample when using the local JAK2 assay indicating limited specificity due to nonspecific amplification Summary / Conclusion: In 24 labs across Europe the detection and quantification of the JAK2-V617F mutation was relatively consistent in patient samples with an allelic burden above 1%. For values below 1% the specificity and thereby the sensitivity of the analysis varied between labs and this was related to the JAK2- V617F assay used.

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Temeljne medicinske znanosti



POVEZANOST RADA


Projekti:
108-1980955-3094 - Genetika i funkcija hematopoeze i mikrookoliša Ph- mijeloproliferativnih bolesti (Kušec, Rajko, MZOS ) ( CroRIS)

Ustanove:
Medicinski fakultet, Zagreb,
Klinička bolnica "Dubrava"

Citiraj ovu publikaciju:

Pallisgaard, Niels; Hasselbach, Hans Carl; Cassinat, A.; Kjaer, Lars; Vorland, M.; Dicker, F.; Bellosillo, Beatriz; Kristensen, T.; Andersen, M.; Lippert, Eric et al.
First European JAK2-V617f interlaboratory quality control study carried out by the MPN&MPNR-Euronet (COST ACTION BM0902) // Abstracts of The 18th Congress of the European Hematology Association ; u: Haematologica 98 (2013) (S1)
Stockholm, Švedska, 2013. str. 115-115 (ostalo, međunarodna recenzija, sažetak, znanstveni)
Pallisgaard, N., Hasselbach, H., Cassinat, A., Kjaer, L., Vorland, M., Dicker, F., Bellosillo, B., Kristensen, T., Andersen, M. & Lippert, E. (2013) First European JAK2-V617f interlaboratory quality control study carried out by the MPN&MPNR-Euronet (COST ACTION BM0902). U: Abstracts of The 18th Congress of the European Hematology Association ; u: Haematologica 98 (2013) (S1).
@article{article, author = {Pallisgaard, Niels and Hasselbach, Hans Carl and Cassinat, A. and Kjaer, Lars and Vorland, M. and Dicker, F. and Bellosillo, Beatriz and Kristensen, T. and Andersen, M. and Lippert, Eric and Schwarz, Jiri and Bryon, J. and Naguib, D. and Nomdedeu, J. and Aggerholm, A. and Wojtaszewska, Marzena and Andrikovics, H and Maru\v{s}i\'{c}, Maru\v{s}ka and Ayala, R and Leibundgut, E and Samuelson, E and Lode, L and Girodon, F and Percy, Melanie and Hermouet, Sylvie}, year = {2013}, pages = {115-115}, keywords = {1849G>T mutation in JAK2, MPN, quantification of JAK2-V617F, COST ACTION BM0902}, title = {First European JAK2-V617f interlaboratory quality control study carried out by the MPN and MPNR-Euronet (COST ACTION BM0902)}, keyword = {1849G>T mutation in JAK2, MPN, quantification of JAK2-V617F, COST ACTION BM0902}, publisherplace = {Stockholm, \v{S}vedska} }
@article{article, author = {Pallisgaard, Niels and Hasselbach, Hans Carl and Cassinat, A. and Kjaer, Lars and Vorland, M. and Dicker, F. and Bellosillo, Beatriz and Kristensen, T. and Andersen, M. and Lippert, Eric and Schwarz, Jiri and Bryon, J. and Naguib, D. and Nomdedeu, J. and Aggerholm, A. and Wojtaszewska, Marzena and Andrikovics, H and Maru\v{s}i\'{c}, Maru\v{s}ka and Ayala, R and Leibundgut, E and Samuelson, E and Lode, L and Girodon, F and Percy, Melanie and Hermouet, Sylvie}, year = {2013}, pages = {115-115}, keywords = {1849G>T mutation in JAK2, MPN, quantification of JAK2-V617F, COST ACTION BM0902}, title = {First European JAK2-V617f interlaboratory quality control study carried out by the MPN and MPNR-Euronet (COST ACTION BM0902)}, keyword = {1849G>T mutation in JAK2, MPN, quantification of JAK2-V617F, COST ACTION BM0902}, publisherplace = {Stockholm, \v{S}vedska} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE





Contrast
Increase Font
Decrease Font
Dyslexic Font